Indications

• Control and Prevention of Hemorrhage in Patients with Factor IX Deficiency (Hemophilia B, Christmas Disease) (see Hemophilia B, [[Hemophilia B]])
• Reversal of Coumadin-Associated Coagulopathy (see Coumadin, [[Coumadin]])
• Reversal of Dabigatran-Associated Coagulopathy (see Dabigatran, [[Dabigatran]])
• Reversal of Rivaroxaban-Associated Coagulopathy (see Rivaroxaban, [[Rivaroxaban]]): abstract from rat study is the only data supporting this treatment

---

Pharmacology

• Content: human plasma derived (lyophilized powder)
  • Factor II
  • Factor IX
  • Factor X
  • Low Amounts of Factor VII

---

Administration

• Dosing: 30 IU/kg IV Push (not to exceed 10 ml/min)

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Allergic/Immunologic Adverse Effects

• Anaphylaxis/Anaphylactoid Reaction (see Anaphylaxis, [[Anaphylaxis]])

Dermatologic Adverse Effects

• Flushing (see Flushing, [[Flushing]])
• Urticaria (see Urticaria-Angioedema, [[Urticaria-Angioedema]])

Gastrointestinal Adverse Effects

• Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]])

Hematologic Adverse Effects

• Thromboembolic Events
  • Deep Venous Thrombosis (DVT)/Acute Pulmonary Embolism (PE) (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]] and Acute Pulmonary Embolism, [[Acute Pulmonary Embolism]])
  • Ischemic Cerebrovascular Accident (CVA) (see Ischemic Cerebrovascular Accident, [[Ischemic Cerebrovascular Accident]])

Neurologic Adverse Effects

• Headache (see Headache, [[Headache]])
• Lethargy/Somnolence (see Obtundation-Coma, [[Obtundation-Coma]])
• Tingling (see Parasthesias, [[Parasthesias]])

Other Adverse Effects

• Fever (see Fever, [[Fever]])
• Rigors (see Rigors, [[Rigors]])
• Transmission of Infectious Agents: as agent is human plasma-derived, the risk of transmission of infectious agents (including viruses and Creutzfeldt-Jakob disease agent) cannot be completely eliminated

---

References

• xxxx